Macitentan for the treatment of severe digital ulcers in a patient with mixed connective tissue disease: avoiding drug interactions

Sirs. Mixed connective tissue disease (MCTD) is a systemic autoimmune disease characterized by polyarthritis, Raynaud’s phenomenon (RP), lung diseases or puffy fingers (1). Treatment of MCTD is a complex process due to the high heterogeneity of clinical manifestations, the need for polypharmacy and risk of toxicity, and drug interactions. Here, we report a case of a 39-year-old woman that has been followed up by our department since she was 21 years old, diagnosed with MCTD, following Alarcón-Segovia (2) and Sharp (3) diagnostic criteria, and antiphospholipid syndrome. She presented RP, myositis, serositis, oesophageal affectation, and moderate interstitial lung disease. On several occasions, she had suffered from moderate vasospasm episodes in both hands with development of digital ulcers (DU). Therefore, she was started on treatment with bosentan, which prevented the occurrence of new DU. During the follow-up, several immunosuppressives were administered, as none of the drugs achieved a complete clinical or biological remission of the disease, and multiple side effects appeared. She reported haematological toxicity caused by azathioprine, hypersensitivity reactions during rituximab perfusion, and mycophenolate mofetil-related enterocolitis. Given her history of drug toxicities and lung and muscle involvement, she started treatment with tacrolimus (2.5-3.0 mg/day in two divided doses) and low-dose corticosteroids (<10 mg/day), which improved muscle and lung involvement without achieving complete clinical or biological remission. Thus, cyclophosphamide administered as bolus was added to the therapy. Despite a good management of DU, treatment with bosentan was discontinued after risk/benefit assessment due to its interaction with tacrolimus (7). Unlike bosentan, macitentan does not interfere with hepatocyte canalicular bile salt-export pump, which avoids a toxic effect on the liver (8). In this scenario, although macitentan is not indicated for the prevention of new DU, but considering a similarity in pharmacological mechanism to bosentan (9), the low incidence of hepatotoxicity and the absence of an established interaction with calcineurin inhibitors, it was administered to the patient with good control of DU. This case suggests that patients with MCTD or systemic sclerosis that presents RP and severe ischaemic DU may benefit from macitentan because it has fewer drug interactions and could show a similar efficacy to bosentan in controlling RP and preventing new DU.

Acknowledgements
We thank Adrià Garriga from TFS s.l. for the English language editing.

C. BUSCA ABENZANA
Á. ROBLES MARHUENDA
A. NOBLEJAS MOZO
C. SOTO ABANADES
E. MARTINEZ ROBLES
J.J. RÍOS BLANCO

Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain.

Please address correspondence and reprint requests to:
Dr Juan José Ríos Blanco,
Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
E-mail: juanjo.rios@gmail.com

Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2019.

References

Letters to the Editors